



**BUREAU OF NATUROPATHIC MEDICINE**  
 1625 North Market Blvd., Suite S-209  
 Sacramento, CA 95834  
 (916) 574-7991 – Office / (916) 574-8645 - FAX



**NATUROPATHIC FORMULARY ADVISORY COMMITTEE**  
**Meeting Minutes**  
 June 4, 2006

**COMMITTEE MEMBERS  
 PRESENT:**

Peter Wannigman, Naturopathic Doctor  
 (Chairman)  
 Soram Khalsa, Medical Doctor (Vice  
 Chair)  
 Mary Hardy, Medical Doctor  
 Cynthia Watson, Medical Doctor  
 Trevor Holly Cates, Naturopathic Doctor  
 Michael Traub, Naturopathic Doctor  
 Paul Mittman, Naturopathic Doctor  
 Larry Woodhouse, Pharmacist

**COMMITTEE MEMBERS  
 ABSENT:**

Arthur Presser, Pharmacist

**STAFF PRESENT:**

Linda Brown  
 Tonya Blood

**I. Call to Order and Roll Call**

Chairman Wannigman called the meeting to order. Roll call was taken and a quorum was present.

**II. Approval of the April 2 and May 7, 2006 Meeting Minutes**

The April 2 meeting minutes were approved as submitted. The May 7 meeting minutes were corrected so that under Other States' Laws, "Iowa" was corrected to read "Idaho." On page 2, under Bureau Report, Item 4, it should be added that the ND to be insured is "employed by" the MD. Also, the word "insurance" was corrected to read "insure". Also, "Dr. Herrier" was changed to read "Dr. Rick Herrier from the University of Arizona College of Pharmacy." Page 3, Item V, "independent prescribing rights" was changed to read "restricted independent prescribing rights." The minutes were approved as corrected.

**III. Chairperson's Report**

Dr. Wannigman reminded the committee that if they do not receive their meeting packet by Friday before the meeting to contact Linda to have the material faxed to them. Linda reminded everyone to let her know whether or not they will be teleconferencing as soon as possible because it holds up the agenda and the packets.

Dr. Wannigman reported on the Advisory Council meeting and stated that it went very well. The IV Formulary was amended to add glandulars, against the vote of the MDs. The Formulary Committee will need to revisit it at a future meeting. Virginia Osborne would be invited back for the discussion. It was also discussed that Michael Smith, a naturopath and

pharmacist and Paul Saunders, a naturopath, may be able to participate. It was tabled for another meeting.

There was discussion about the ability of the Advisory Council, with lay members, being able to override a decision of an expert committee, and it was stated that Dr. Hangee-Bauer needed to develop a policy or protocol so that it would not happen in the future.

Dr. Wannigman also stated that the Formulary Committee is not dissolved on January 1, 2007.

Dr. Wannigman asked if the Bureau had documentation from NCMIC regarding any malpractice issues. Dr. Traub said he would follow up on it. The Bureau is also going to collect data from ND licensing boards in other states regarding discipline.

Dr. Wannigman also asked members to review the information on the AZNMA pharmacology site to review the material there for a vote on the 60-hour pharmacology course material at the next meeting.

It was discussed that NABNE is not changing the pharmaceutical portion of the NPLEX.

Dr. Mittman was reminded to provide Linda with "Why NDs Need to Prescribe." Dr. Mittman stated it was high on his to-do list and would be done before the next meeting.

#### **IV. Bureau Report**

Linda stated that the Bureau may end the fiscal year with a few thousand dollars in the black but that has yet to be determined.

#### **V. Review/Discussion of Responses from Malpractice Insurance Companies Regarding Insurance for NDs and Supervising MDs**

The committee reviewed the responses received from the malpractices companies that have responded to the Bureau's questionnaire. Dr. Khalsa stated he would present a scenario to his malpractice company to see what their response would be.

#### **VI. Discussion Regarding Request for Written Statement from Pharmacy Board on Substances/Routes of Administration**

Tabled.

**VII. Discussion of Inclusionary/Exclusionary Pharmaceutical Formulary for Recommendation**

The committee reviewed both the inclusionary and exclusionary formulary lists provided in the meeting packets. The committee went through the inclusionary list and moved several drug categories from the inclusionary list to the exclusionary list. The committee will review the last category, Respiratory Agents, at the next meeting.

**VIII. Future Meeting Dates**

The next meeting will be at Dr. Khalsa's office on July 23 at 10 a.m.

**IX. Public Comment**

There was no public comment.

**X. Adjournment**

The meeting was adjourned.